Phage Therapy Beyond Static Pharmaceuticals: A Framework for Controlled Evolutionary Platforms.

Area of Science:

• Microbiology
• Virology
• Biotechnology

Background:

• Antimicrobial resistance necessitates novel therapeutic strategies, increasing interest in phage therapy.
• Clinical integration of phage therapy is hindered by regulatory challenges stemming from an "evaluation mismatch."
• Current regulations treat bacteriophages (phages) as static entities, overlooking their dynamic, evolving nature.

Purpose of the Study:

• To address the conceptual barrier in phage therapy evaluation.
• To propose a novel framework for managing phage evolution in clinical settings.
• To redefine consistency in phage therapy from genetic stability to reliable population dynamics.

Main Methods:

• Utilizing Schrödinger's cat metaphor to illustrate phage variability as an inherent feature.
• Proposing a Controlled Evolutionary Platform (CEP).
• Differentiating between a fixed "Safety Core" and a fluctuating "Adaptive Periphery" within the phage population.

Main Results:

• Phage variability is an essential characteristic, not a defect, crucial for therapeutic efficacy.
• The Controlled Evolutionary Platform offers a method to manage, rather than suppress, viral evolution.
• The CEP framework distinguishes between stable genetic elements and adaptable components.

Conclusions:

• Overcoming the "evaluation mismatch" requires a paradigm shift in regulatory approaches to phage therapy.
• Integrating phages into medicine necessitates redefining consistency to focus on predictable population dynamics.
• The proposed framework facilitates the transition of phage therapy into standard clinical practice by embracing, not resisting, evolution.